

alkynyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.

[0016a] At least one embodiment provides a composition comprising at least one of the following compounds:

N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(3-fluorophenyl)methyl]-2-methylbenzimidazol-4-yl]ethanesulfonamide;
N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(4-fluorophenyl)methyl]indazol-4-yl]ethanesulfonamide;
N-[2-cyclopropyl-7-(2-methyl-1-oxoisoquinolin-4-yl)-1,3-benzoxazol-5-yl]ethanesulfonamide;
N-[2-cyclopropyl-7-(2-methyl-1-oxoisoquinolin-4-yl)-1-benzofuran-5-yl]methanesulfonamide;
N-[2-cyclopropyl-7-(2-methyl-1-oxoisoquinolin-4-yl)-1-benzofuran-5-yl]ethanesulfonamide;
N-[7-(2-methyl-1-oxoisoquinolin-4-yl)-2-phenyl-1-benzofuran-5-yl]methanesulfonamide;
4-[5-(cyclopropylmethoxy)-2-ethyl-1,1-dioxo-3H-1,2-benzothiazol-6-yl]-2-methylisoquinolin-1-one;
4-[5-(cyclopropylmethoxy)-1-methylsulfonyl-2,3-dihydroindol-6-yl]-2-methylisoquinolin-1-one;
4-[5-(cyclopropylmethoxy)-1-ethylsulfonyl-2,3-dihydroindol-6-yl]-2-methylisoquinolin-1-one;
N-[1-benzyl-6-(2-methyl-1-oxoisoquinolin-4-yl)indol-4-yl]methanesulfonamide;
N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)indol-4-yl]methanesulfonamide;
N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dihydroindol-4-yl]methanesulfonamide;
N-[1-benzyl-6-(2-methyl-1-oxoisoquinolin-4-yl)-2,3-dihydroindol-4-yl]methanesulfonamide;
4-(2-cyclopropyl-5-methylsulfonyl-1-benzofuran-7-yl)-2-methylisoquinolin-1-one;
2-methyl-4-(5-methylsulfonyl-2-phenyl-1-benzofuran-7-yl)isoquinolin-1-one;
N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)benzotriazol-4-yl]ethanesulfonamide
N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(4-fluorophenyl)methyl]benzotriazol-4-yl]ethanesulfonamide;
4-[6-(cyclopropylmethoxy)-1-methyl-3-methylsulfonylindazol-5-yl]-2-methylisoquinolin-1-one;

4-[6-(cyclopropylmethoxy)-3-ethylsulfonyl-1-methylindazol-5-yl]-2-methylisoquinolin-1-one;
 N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)benzimidazol-4-yl]methanesulfonamide
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(3-fluorophenyl)methyl]benzimidazol-4-yl]methanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(3-fluorophenyl)methyl]benzimidazol-4-yl]ethanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(3-fluorophenyl)methyl]-2-methylbenzimidazol-4-yl]methanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(4-fluorophenyl)methyl]-2-methylbenzimidazol-4-yl]methanesulfonamide;
 N-[1-[(2,4-difluorophenyl)methyl]-6-(1,5-dimethyl-6-oxopyridin-3-yl)benzimidazol-4-yl]ethanesulfonamide;
 N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)indazol-4-yl]ethanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-methyl-1-(1-phenylethyl)benzimidazol-4-yl]methanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-methyl-1-(1-phenylethyl)benzimidazol-4-yl]methanesulfonamide;
 4-[7-(cyclopropylmethoxy)-4-ethylsulfonyl-2,3-dihydro-1,4-benzoxazin-6-yl]-2-methylisoquinolin-1-one;
 N-[1-(cyclopropylmethyl)-6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-ethoxybenzimidazol-4-yl]methanesulfonamide;
 N-[1-(cyclopropylmethyl)-6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-methoxybenzimidazol-4-yl]methanesulfonamide;
 N-[2-cyclopropyl-7-(1,5-dimethyl-6-oxopyridin-3-yl)-1-benzofuran-5-yl]methanesulfonamide;
 N-[1-(cyclopropylmethyl)-6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-(trifluoromethyl)benzimidazol-4-yl]methanesulfonamide;
 4-(2-ethyl-5-methylsulfonyl-1-benzofuran-7-yl)-2-methylisoquinolin-1-one;
 N-[2-cyclopropyl-7-(1,5-dimethyl-6-oxopyridin-3-yl)-1-benzofuran-5-yl]ethanesulfonamide;
 or a pharmaceutical salt of any of these.

[0017] At least one embodiment provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. At least one embodiment

provides a pharmaceutical composition comprising a compound of Formula II, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula III, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula IV, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula IVa, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula Va, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula Vb, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula Vc, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula Vd, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula Ve, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a pharmaceutical composition comprising a compound of Formula VI, or a pharmaceutically acceptable salt thereof.

[0018] At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula II, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula III, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula IV, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula IVa, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient

in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula Va, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula Vb, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula Vc, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula Vd, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula Ve, or a pharmaceutically acceptable salt thereof. At least one embodiment provides a method of treating a cancer patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula VI, or a pharmaceutically acceptable salt thereof.

[0018a] At least one embodiment provides a pharmaceutical composition comprising the compound as characterized in any one of the preceding claims.

[0018b] At least one embodiment provides an oral dosage form comprising the pharmaceutical composition as disclosed herein.

[0018c] At least one embodiment provides a medicament comprising the pharmaceutical composition as disclosed herein for use in the treatment of cancer or other neoplastic disease.

[0018d] At least one embodiment provides use of a compound or pharmaceutical composition as disclosed herein for preparation of a medicament for treating cancer or other neoplastic disease.

[0018e] At least one embodiment provides a method of modulating the epigenetic status of a cell comprising contacting the cell with the compound as disclosed herein.

[0018f] At least one embodiment provides a method for inhibiting a histone demethylase enzyme comprising contacting a histone demethylase enzyme with the compound as disclosed herein.

DETAILED DESCRIPTION

[0019] It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[0020] All patents and other publications identified are incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the present invention, but are not to provide definitions of terms inconsistent with those presented herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on information available to the applicants and do not constitute any admission as to the correctness of the dates or contents of these documents.


[0021] As used herein and in the claims, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly indicates otherwise. Throughout this specification, unless otherwise indicated, “comprise,” “comprises” and “comprising” are used inclusively

Y is selected from a bond, $-\text{CH}_2-$, or $-\text{CH}(\text{C}_1\text{-C}_4 \text{ alkyl})-$, and
 Z is selected from $-\text{SO}_2\text{R}^b$, $-\text{N}(\text{R}^a)\text{SO}_2\text{R}^b$, $-\text{SO}_2\text{N}(\text{R}^a)_2$, $-\text{N}(\text{R}^a)\text{SO}_2\text{N}(\text{R}^a)_2$,
 $-\text{CON}(\text{R}^a)_2$, $-\text{N}(\text{R}^a)\text{CO}_2\text{R}^a$, $-\text{N}(\text{R}^a)\text{CON}(\text{R}^a)_2$, $-\text{N}(\text{R}^a)\text{COR}^a$, $-\text{OC}(\text{O})\text{N}(\text{R}^a)_2$,
 $-\text{OSO}_2\text{N}(\text{R}^a)_2$, or $-\text{N}(\text{R}^a)\text{SO}_3\text{R}^b$, each R^a is independently hydrogen, alkyl,
 cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl,
 heteroaryl, or heteroarylalkyl, and R^b is selected from alkyl, cycloalkyl,
 cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or
 heteroarylalkyl; and

X6 is N or C-R^{16} , in which R^{16} is hydrogen, halogen, or $-\text{W-X}$, wherein

W is a bond, $-\text{O}-$, $-\text{S}-$, or $-\text{NH}-$, and X is selected from alkyl, alkynyl, aryl,
 aralkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkynyl, heterocyclyl,
 heterocyclylalkyl, heteroaryl, or heteroarylalkyl.

54. A compound of Formula Vc, or a pharmaceutically acceptable salt thereof,



Formula Vc

wherein:

Ring C is an optionally substituted 5- or 6-membered heteroaryl ring containing at least one O, S or N atom;

X2 is N or C-R^{12} , in which R^{12} is hydrogen, halogen, alkyl, or alkoxy;

X3 is N or C-R^{13} , in which R^{13} is $-\text{Y-Z}$, in which

Y is a bond, $-\text{CH}_2-$, or $-\text{CH}(\text{C}_1\text{-C}_4 \text{ alkyl})-$, and


Z is $-\text{SO}_2\text{R}^b$, $-\text{N}(\text{R}^a)\text{SO}_2\text{R}^b$, $-\text{SO}_2\text{N}(\text{R}^a)_2$, $-\text{N}(\text{R}^a)\text{SO}_2\text{N}(\text{R}^a)_2$, $-\text{CON}(\text{R}^a)_2$,
 $-\text{N}(\text{R}^a)\text{CO}_2\text{R}^a$, $-\text{N}(\text{R}^a)\text{CON}(\text{R}^a)_2$, $-\text{N}(\text{R}^a)\text{COR}^a$, $-\text{OC}(\text{O})\text{N}(\text{R}^a)_2$, $-\text{OSO}_2\text{N}(\text{R}^a)_2$, or
 $-\text{N}(\text{R}^a)\text{SO}_3\text{R}^b$, wherein

each R^a is independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl,
 aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or
 heteroarylalkyl, and

R^b is selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl,
 heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; and

X4 is N or C-R^{14} , in which R^{14} is hydrogen, halogen, $-\text{CN}$, alkyl, cycloalkyl, or alkoxy.

55. A compound of Formula Ve:



or a pharmaceutically acceptable salt thereof, wherein

J is N or C-R¹², in which R¹² is hydrogen, halogen, alkyl, or alkoxy;


R¹³ is -Y-Z, in which Y is a bond, -CH₂-, or -CH(C₁-C₄alkyl)-, and Z is -SO₂R²¹, -N(R²²)SO₂R²¹, -SO₂N(R²²)₂, -N(R²²)SO₂N(R²²)₂, -CON(R²²)₂, -N(R²²)CO₂R²¹, -N(R²²)CON(R²²)₂, -N(R²²)COR²¹, -COR²¹, -OC(O)N(R²²)₂, -OSO₂N(R²²)₂, or -N(R²²)SO₃R²¹, in which each R²¹ is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and wherein each R²² is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

K is N or C-R¹⁴, in which R¹⁴ is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy;

Q is N or C-R¹⁵, in which R¹⁵ is hydrogen, halogen, -CN, alkyl, alkoxy, aryloxy, aralkyloxy, cycloalkylalkyloxy, heterocycliloxy, heteroarylalkyloxy, or alkynyloxy; and

R¹⁶ is hydrogen, halogen, -N(H)COX, or -W-X, wherein W is a bond, -O-, -S-, or -NH-, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkynyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.

56. A compound of Formula VI, or a pharmaceutically acceptable salt thereof, in which Formula VI is:



wherein

n is 0 to 4;

m is 0 or 1;

R^A is a halogen, C1-3 alkyl, or C1-3 alkoxy;

J is N or C-R¹², wherein R¹² is hydrogen, halogen, alkyl, or alkoxy;

R¹³ is -Y-Z, in which

Y is a bond, -CH₂-, or -CH(C₁-C₄alkyl)-, and

Z is -SO₂R²¹, -N(R²²)SO₂R²¹, -SO₂N(R²²)₂, -N(R²²)SO₂N(R²²)₂, -CON(R²²)₂,
-N(R²²)CO₂R²¹, -N(R²²)CON(R²²)₂, -N(R²²)COR²¹, -COR²¹, -OC(O)N(R²²)₂,
-OSO₂N(R²²)₂, or -N(R²²)SO₃R²¹,

wherein each R²¹ is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl,
aralkyl, heterocyclyl, heterocyclalkyl, heteroaryl, or heteroarylalkyl, and
each R²² is independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl,
aryl, aralkyl, heterocyclyl, heterocyclalkyl, heteroaryl,
or heteroarylalkyl.

K is N or C-R¹⁴, wherein R¹⁴ is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy;

Q is N or C-R¹⁵, wherein R¹⁵ is hydrogen, halogen, -CN, alkyl, alkoxy, aryloxy,
aralkyloxy, cycloalkylalkyloxy, heterocyclloxy, heteroarylalkyloxy, or alkynyloxy; and

R¹⁶ is hydrogen, halogen, -N(H)COX, or -W-X, wherein W is a bond, -O-, -S-, or
-NH-, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkynyl,
cycloalkylalkynyl, heterocyclyl, heterocyclalkyl, heteroaryl, or heteroarylalkyl.

57. A composition comprising at least one of the following compounds:

N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(3-fluorophenyl)methyl]-2-
methylbenzimidazol-4-yl]ethanesulfonamide;

N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(4-fluorophenyl)methyl]indazol-4-
yl]ethanesulfonamide;

N-[2-cyclopropyl-7-(2-methyl-1-oxoisoquinolin-4-yl)-1,3-benzoxazol-5-
yl]ethanesulfonamide;

N-[2-cyclopropyl-7-(2-methyl-1-oxoisoquinolin-4-yl)-1-benzofuran-5-
yl]methanesulfonamide;

N-[2-cyclopropyl-7-(2-methyl-1-oxoisoquinolin-4-yl)-1-benzofuran-5-
yl]ethanesulfonamide;

N-[7-(2-methyl-1-oxoisoquinolin-4-yl)-2-phenyl-1-benzofuran-5-
yl]methanesulfonamide;

4-[5-(cyclopropylmethoxy)-2-ethyl-1,1-dioxo-3H-1,2-benzothiazol-6-yl]-2-
methylisoquinolin-1-one;

4-[5-(cyclopropylmethoxy)-1-methylsulfonyl-2,3-dihydroindol-6-yl]-2-
methylisoquinolin-1-one;

4-[5-(cyclopropylmethoxy)-1-ethylsulfonyl-2,3-dihydroindol-6-yl]-2-methylisoquinolin-1-one;
 N-[1-benzyl-6-(2-methyl-1-oxoisoquinolin-4-yl)indol-4-yl]methanesulfonamide;
 N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)indol-4-yl]methanesulfonamide;
 N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dihydroindol-4-yl]methanesulfonamide;
 N-[1-benzyl-6-(2-methyl-1-oxoisoquinolin-4-yl)-2,3-dihydroindol-4-yl]methanesulfonamide;
 4-(2-cyclopropyl-5-methylsulfonyl-1-benzofuran-7-yl)-2-methylisoquinolin-1-one;
 2-methyl-4-(5-methylsulfonyl-2-phenyl-1-benzofuran-7-yl)isoquinolin-1-one;
 N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)benzotriazol-4-yl]ethanesulfonamide
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(4-fluorophenyl)methyl]benzotriazol-4-yl]ethanesulfonamide;
 4-[6-(cyclopropylmethoxy)-1-methyl-3-methylsulfonylindazol-5-yl]-2-methylisoquinolin-1-one;
 4-[6-(cyclopropylmethoxy)-3-ethylsulfonyl-1-methylindazol-5-yl]-2-methylisoquinolin-1-one;
 N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)benzimidazol-4-yl]methanesulfonamide
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(3-fluorophenyl)methyl]benzimidazol-4-yl]methanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(3-fluorophenyl)methyl]benzimidazol-4-yl]ethanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(3-fluorophenyl)methyl]-2-methylbenzimidazol-4-yl]methanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-1-[(4-fluorophenyl)methyl]-2-methylbenzimidazol-4-yl]methanesulfonamide;
 N-[1-[(2,4-difluorophenyl)methyl]-6-(1,5-dimethyl-6-oxopyridin-3-yl)benzimidazol-4-yl]ethanesulfonamide;
 N-[1-benzyl-6-(1,5-dimethyl-6-oxopyridin-3-yl)indazol-4-yl]ethanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-methyl-1-(1-phenylethyl)benzimidazol-4-yl]methanesulfonamide;
 N-[6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-methyl-1-(1-phenylethyl)benzimidazol-4-yl]methanesulfonamide;
 4-[7-(cyclopropylmethoxy)-4-ethylsulfonyl-2,3-dihydro-1,4-benzoxazin-6-yl]-2-methylisoquinolin-1-one;

N-[1-(cyclopropylmethyl)-6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-ethoxybenzimidazol-4-yl]methanesulfonamide;

N-[1-(cyclopropylmethyl)-6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-methoxybenzimidazol-4-yl]methanesulfonamide;

N-[2-cyclopropyl-7-(1,5-dimethyl-6-oxopyridin-3-yl)-1-benzofuran-5-yl]methanesulfonamide;

N-[1-(cyclopropylmethyl)-6-(1,5-dimethyl-6-oxopyridin-3-yl)-2-(trifluoromethyl)benzimidazol-4-yl]methanesulfonamide;

4-(2-ethyl-5-methylsulfonyl-1-benzofuran-7-yl)-2-methylisoquinolin-1-one;

N-[2-cyclopropyl-7-(1,5-dimethyl-6-oxopyridin-3-yl)-1-benzofuran-5-yl]ethanesulfonamide;

or a pharmaceutical salt of any of these.

58. A pharmaceutical composition comprising the compound as characterized in any one of the preceding claims.

59. The pharmaceutical composition of claim 58, wherein the compound is 4-(2-ethyl-5-(methylsulfonyl)benzofuran-7-yl)-2-methylisoquinolin-1(2H)-one, or a pharmaceutically acceptable salt thereof; or 4-(2-cyclopropyl-5-(methylsulfonyl)benzofuran-7-yl)-2-methylisoquinolin-1(2H)-one, or a pharmaceutically acceptable salt thereof.

60. An oral dosage form comprising the pharmaceutical composition of claim 58.

61. A medicament comprising the pharmaceutical composition of claim 58 for use in the treatment of cancer or other neoplastic disease.

62. Use of a compound or pharmaceutical composition of any one of the preceding claims for preparation of a medicament for treating cancer or other neoplastic disease.

63. A method of modulating the epigenetic status of a cell comprising contacting the cell with the compound of any one of claims 1-57.

64. A method for inhibiting a histone demethylase enzyme comprising contacting a histone demethylase enzyme with the compound of any one of claims 1-57.